ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Gilda Sandri, Valentina Cestelli, Maria Teresa Mascia
Data from literature show that the overall risk of cancer does not as a result from treatment with these drugs. The only cancer for which various authors have reported an increased risk, in some cases, are skin cancers, different from melanoma and melanoma. R…
Luis F. Porrata, Kay M. Ristow, Thomas M. Habermann, Thomas E. Witzig, Joseph P. Colgan, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Grzegorz Nowakowski, Carrie A. Thompson, Svetomir N. Markovic
Interim Positron-Emission Tomography (int-PET) and the peripheral blood absolute lymphocyte/monocyte ratio at di - agnosis (ALC/AMC-DX) have been shown to be predictors for progression-free survival (PFS) and time to progression (TTP) in classical Hodgkin lym…
Junya Miyahara, Naoki Takezako, Miyuki Wagatsuma, Kiyoe Midorikawa, Ichiro Fukuda, Satoshi Noto, Ikuo Saito, Kazuaki Yamada, Akiyoshi Miwa, Naohiro Sekiguchi
The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) recurrence is still poor. A standard treatment for CD20+ DLBCL with CNS recurrence in elderly patients has not been established mainly due to advers…
Lin Lin, Xiaofei Sun, Juan Wang, Zijun Zhen, Suxia Lin, Gangling Tong, Yan Chen
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) is commonly associated with Notch 1 mutations. There is limited data on the relationship between Notch l and NF- κ B expression and clinical features in LBL. We evaluated the expression of Notch l and…
Kimberly Terry, Mehmet Sitki Copur
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related mortality worldwide. Despite decades of efforts by many investigators, systemic chemotherapy or hormonal therapy has notoriously failed to show an…
Mitsuru Futakuchi
We observed that N-nitrosomorpholine (NMOR) given after a multi-carcinogenic treatment induces liver carcinomas with 56% lung metastasis. An additional treatment with diethylnitrosamine (DEN) with NMOR further enhanced the incidence of hepatocellular carcinom…
Alessandra Tovoli, Lucia Napoli, Marianna Mastroroberto, Matteo Renzulli, Manuel Tufoni, Carmen Serena Ricci, Rita Golfieri, Giovanni Brandi
Trans-arterial chemoembolization (TACE) has been established as the standard of care for patients with intermediate stage of multinodular hepatocellular carcinoma (HCC), according to Barcelona Clinic Liver Cancer (BCLC) classification, and no extra-hepatic di…
Toru Ishikawa
Hepatocellular carcinoma (HCC) has some unique characteristics in the digestive organ cancer. Therefore it is very important to select an appropriate treatment for recurrent HCC according to several s itu ations such as the type of recurrence, previous treatm…
Renumathy Dhanasekaran, Davinderbir S. Pannu, Alpna Limaye, Ivan Zendejas, Roberto J. Firpi, Consuelo Soldevila-Pico, Giuseppe Morelli, Virginia C. Clark, Amitabh Suman, David R. Nelson, Roniel Cabrera
Incidentally discovered hepatocellular carcinomas (iHCC) are tumors which are discovered on the explanted liver which were not present on imaging prior to transplant. The natural history, histopathologic characteristics and prognosis of iHCC are not clearly d…
Raphael Raphe, Willian J. Duca, Paulo C. Arroyo Jr., Rita C. da Silva, Renato F. da Silva
Introduction: Hepatocellular carcinoma is the most common primary neoplasm of the liver and a significant cause of mortality in patients with cirrhosis. A retrospective cross-sectional study was performed to analyze epidemiological aspects related to risk fac…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).